nodes	percent_of_prediction	percent_of_DWPC	metapath
Pentoxifylline—CYP1A2—Carmustine—melanoma	0.144	0.417	CbGbCtD
Pentoxifylline—CYP1A2—Vemurafenib—melanoma	0.114	0.33	CbGbCtD
Pentoxifylline—CYP1A2—Dacarbazine—melanoma	0.0872	0.253	CbGbCtD
Pentoxifylline—PDE5A—clitoris—melanoma	0.0735	0.475	CbGeAlD
Pentoxifylline—PDE5A—endothelium—melanoma	0.00814	0.0526	CbGeAlD
Pentoxifylline—PDE5A—blood vessel—melanoma	0.00751	0.0485	CbGeAlD
Pentoxifylline—NT5E—eye—melanoma	0.00616	0.0398	CbGeAlD
Pentoxifylline—NT5E—retina—melanoma	0.0061	0.0394	CbGeAlD
Pentoxifylline—NT5E—skin of body—melanoma	0.00536	0.0346	CbGeAlD
Pentoxifylline—ADORA2B—eye—melanoma	0.00527	0.0341	CbGeAlD
Pentoxifylline—NT5E—mammalian vulva—melanoma	0.00488	0.0316	CbGeAlD
Pentoxifylline—Caffeine—ATM—melanoma	0.00441	0.256	CrCbGaD
Pentoxifylline—ADORA2B—mammalian vulva—melanoma	0.00418	0.027	CbGeAlD
Pentoxifylline—Caffeine—PIK3CB—melanoma	0.00404	0.234	CrCbGaD
Pentoxifylline—Caffeine—PIK3CD—melanoma	0.00404	0.234	CrCbGaD
Pentoxifylline—PDE5A—eye—melanoma	0.004	0.0258	CbGeAlD
Pentoxifylline—PDE5A—retina—melanoma	0.00396	0.0256	CbGeAlD
Pentoxifylline—NT5E—head—melanoma	0.00349	0.0226	CbGeAlD
Pentoxifylline—Caffeine—PIK3CA—melanoma	0.00312	0.181	CrCbGaD
Pentoxifylline—ADORA2B—head—melanoma	0.00299	0.0193	CbGeAlD
Pentoxifylline—ADORA2A—head—melanoma	0.00249	0.0161	CbGeAlD
Pentoxifylline—NT5E—lymph node—melanoma	0.00245	0.0158	CbGeAlD
Pentoxifylline—PDE5A—head—melanoma	0.00227	0.0147	CbGeAlD
Pentoxifylline—PDE4B—mammalian vulva—melanoma	0.00222	0.0144	CbGeAlD
Pentoxifylline—ADORA1—head—melanoma	0.00215	0.0139	CbGeAlD
Pentoxifylline—PDE4A—lymph node—melanoma	0.00187	0.0121	CbGeAlD
Pentoxifylline—Back pain—Vemurafenib—melanoma	0.00161	0.00733	CcSEcCtD
Pentoxifylline—PDE4B—head—melanoma	0.00159	0.0103	CbGeAlD
Pentoxifylline—PDE5A—lymph node—melanoma	0.00159	0.0103	CbGeAlD
Pentoxifylline—Vascular purpura—Temozolomide—melanoma	0.00158	0.00719	CcSEcCtD
Pentoxifylline—Nasal congestion—Temozolomide—melanoma	0.00155	0.00706	CcSEcCtD
Pentoxifylline—ADORA1—lymph node—melanoma	0.00151	0.00973	CbGeAlD
Pentoxifylline—Thirst—Temozolomide—melanoma	0.00148	0.00676	CcSEcCtD
Pentoxifylline—Purpura—Temozolomide—melanoma	0.00146	0.00668	CcSEcCtD
Pentoxifylline—Bronchospasm—Bleomycin—melanoma	0.00142	0.00648	CcSEcCtD
Pentoxifylline—Oropharyngeal pain—Docetaxel—melanoma	0.00142	0.00648	CcSEcCtD
Pentoxifylline—Myalgia—Vemurafenib—melanoma	0.00142	0.00645	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00141	0.00641	CcSEcCtD
Pentoxifylline—Lacrimation increased—Docetaxel—melanoma	0.0014	0.0064	CcSEcCtD
Pentoxifylline—Pancytopenia—Bleomycin—melanoma	0.00137	0.00626	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Vemurafenib—melanoma	0.00136	0.00619	CcSEcCtD
Pentoxifylline—Infection—Vemurafenib—melanoma	0.00135	0.00615	CcSEcCtD
Pentoxifylline—Skin disorder—Vemurafenib—melanoma	0.00132	0.00601	CcSEcCtD
Pentoxifylline—Pancytopenia—Dactinomycin—melanoma	0.00128	0.00584	CcSEcCtD
Pentoxifylline—Caffeine—CYP1B1—melanoma	0.00127	0.0736	CrCbGaD
Pentoxifylline—Hypotension—Vemurafenib—melanoma	0.00127	0.00578	CcSEcCtD
Pentoxifylline—Influenza like illness—Docetaxel—melanoma	0.00126	0.00572	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00124	0.00564	CcSEcCtD
Pentoxifylline—Abdominal distension—Temozolomide—melanoma	0.00123	0.0056	CcSEcCtD
Pentoxifylline—Pancytopenia—Carmustine—melanoma	0.0012	0.00547	CcSEcCtD
Pentoxifylline—Decreased appetite—Vemurafenib—melanoma	0.00118	0.00538	CcSEcCtD
Pentoxifylline—Haemoglobin—Bleomycin—melanoma	0.00116	0.0053	CcSEcCtD
Pentoxifylline—Constipation—Vemurafenib—melanoma	0.00116	0.00529	CcSEcCtD
Pentoxifylline—Pancytopenia—Temozolomide—melanoma	0.00116	0.00528	CcSEcCtD
Pentoxifylline—Haemorrhage—Bleomycin—melanoma	0.00116	0.00528	CcSEcCtD
Pentoxifylline—Lightheadedness—Docetaxel—melanoma	0.00116	0.00527	CcSEcCtD
Pentoxifylline—PDE4B—lymph node—melanoma	0.00111	0.0072	CbGeAlD
Pentoxifylline—Infestation NOS—Temozolomide—melanoma	0.00109	0.00496	CcSEcCtD
Pentoxifylline—Infestation—Temozolomide—melanoma	0.00109	0.00496	CcSEcCtD
Pentoxifylline—Hepatitis—Dactinomycin—melanoma	0.00108	0.00492	CcSEcCtD
Pentoxifylline—Flushing—Bleomycin—melanoma	0.00107	0.0049	CcSEcCtD
Pentoxifylline—Body temperature increased—Vemurafenib—melanoma	0.00107	0.00489	CcSEcCtD
Pentoxifylline—Swelling—Docetaxel—melanoma	0.00106	0.00485	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Temozolomide—melanoma	0.00103	0.00469	CcSEcCtD
Pentoxifylline—Haemoglobin—Carmustine—melanoma	0.00102	0.00463	CcSEcCtD
Pentoxifylline—Haemorrhage—Carmustine—melanoma	0.00101	0.00461	CcSEcCtD
Pentoxifylline—Erythema—Bleomycin—melanoma	0.00101	0.00459	CcSEcCtD
Pentoxifylline—Flushing—Dactinomycin—melanoma	0.001	0.00457	CcSEcCtD
Pentoxifylline—Hypersensitivity—Vemurafenib—melanoma	0.001	0.00456	CcSEcCtD
Pentoxifylline—Haemoglobin—Temozolomide—melanoma	0.000981	0.00447	CcSEcCtD
Pentoxifylline—Haemorrhage—Temozolomide—melanoma	0.000976	0.00445	CcSEcCtD
Pentoxifylline—Hepatitis—Temozolomide—melanoma	0.000976	0.00445	CcSEcCtD
Pentoxifylline—Asthenia—Vemurafenib—melanoma	0.000974	0.00444	CcSEcCtD
Pentoxifylline—Pruritus—Vemurafenib—melanoma	0.00096	0.00438	CcSEcCtD
Pentoxifylline—Erythema—Dactinomycin—melanoma	0.00094	0.00428	CcSEcCtD
Pentoxifylline—Flushing—Carmustine—melanoma	0.000938	0.00427	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Bleomycin—melanoma	0.000935	0.00426	CcSEcCtD
Pentoxifylline—Anaemia—Bleomycin—melanoma	0.000931	0.00425	CcSEcCtD
Pentoxifylline—Diarrhoea—Vemurafenib—melanoma	0.000929	0.00423	CcSEcCtD
Pentoxifylline—Malaise—Bleomycin—melanoma	0.000909	0.00414	CcSEcCtD
Pentoxifylline—Flushing—Temozolomide—melanoma	0.000906	0.00413	CcSEcCtD
Pentoxifylline—Arrhythmia—Carmustine—melanoma	0.000903	0.00411	CcSEcCtD
Pentoxifylline—Leukopenia—Bleomycin—melanoma	0.000902	0.00411	CcSEcCtD
Pentoxifylline—Dizziness—Vemurafenib—melanoma	0.000898	0.00409	CcSEcCtD
Pentoxifylline—Immune system disorder—Temozolomide—melanoma	0.000882	0.00402	CcSEcCtD
Pentoxifylline—Erythema—Carmustine—melanoma	0.00088	0.00401	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Dactinomycin—melanoma	0.000872	0.00398	CcSEcCtD
Pentoxifylline—Anaemia—Dactinomycin—melanoma	0.000869	0.00396	CcSEcCtD
Pentoxifylline—Vomiting—Vemurafenib—melanoma	0.000863	0.00393	CcSEcCtD
Pentoxifylline—Chest pain—Bleomycin—melanoma	0.000858	0.00391	CcSEcCtD
Pentoxifylline—Myalgia—Bleomycin—melanoma	0.000858	0.00391	CcSEcCtD
Pentoxifylline—Rash—Vemurafenib—melanoma	0.000856	0.0039	CcSEcCtD
Pentoxifylline—Dermatitis—Vemurafenib—melanoma	0.000855	0.0039	CcSEcCtD
Pentoxifylline—Back pain—Carmustine—melanoma	0.000851	0.00388	CcSEcCtD
Pentoxifylline—Headache—Vemurafenib—melanoma	0.00085	0.00388	CcSEcCtD
Pentoxifylline—Erythema—Temozolomide—melanoma	0.00085	0.00387	CcSEcCtD
Pentoxifylline—Discomfort—Bleomycin—melanoma	0.000848	0.00386	CcSEcCtD
Pentoxifylline—Malaise—Dactinomycin—melanoma	0.000847	0.00386	CcSEcCtD
Pentoxifylline—Leukopenia—Dactinomycin—melanoma	0.000841	0.00383	CcSEcCtD
Pentoxifylline—Dysgeusia—Temozolomide—melanoma	0.000832	0.00379	CcSEcCtD
Pentoxifylline—Confusional state—Bleomycin—melanoma	0.000829	0.00378	CcSEcCtD
Pentoxifylline—Vision blurred—Carmustine—melanoma	0.000829	0.00378	CcSEcCtD
Pentoxifylline—Tremor—Carmustine—melanoma	0.000824	0.00376	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Bleomycin—melanoma	0.000822	0.00375	CcSEcCtD
Pentoxifylline—Oedema—Bleomycin—melanoma	0.000822	0.00375	CcSEcCtD
Pentoxifylline—Back pain—Temozolomide—melanoma	0.000822	0.00375	CcSEcCtD
Pentoxifylline—Infection—Bleomycin—melanoma	0.000817	0.00372	CcSEcCtD
Pentoxifylline—Anaemia—Carmustine—melanoma	0.000813	0.00371	CcSEcCtD
Pentoxifylline—Agitation—Carmustine—melanoma	0.000808	0.00368	CcSEcCtD
Pentoxifylline—Nausea—Vemurafenib—melanoma	0.000806	0.00368	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Bleomycin—melanoma	0.000805	0.00367	CcSEcCtD
Pentoxifylline—Vision blurred—Temozolomide—melanoma	0.000801	0.00365	CcSEcCtD
Pentoxifylline—Myalgia—Dactinomycin—melanoma	0.0008	0.00365	CcSEcCtD
Pentoxifylline—Bronchospasm—Docetaxel—melanoma	0.000798	0.00364	CcSEcCtD
Pentoxifylline—Tremor—Temozolomide—melanoma	0.000796	0.00363	CcSEcCtD
Pentoxifylline—Discomfort—Dactinomycin—melanoma	0.000791	0.0036	CcSEcCtD
Pentoxifylline—Angina pectoris—Docetaxel—melanoma	0.00079	0.0036	CcSEcCtD
Pentoxifylline—Ill-defined disorder—Temozolomide—melanoma	0.000789	0.0036	CcSEcCtD
Pentoxifylline—Leukopenia—Carmustine—melanoma	0.000787	0.00359	CcSEcCtD
Pentoxifylline—Anaemia—Temozolomide—melanoma	0.000786	0.00358	CcSEcCtD
Pentoxifylline—Anorexia—Bleomycin—melanoma	0.000784	0.00357	CcSEcCtD
Pentoxifylline—Agitation—Temozolomide—melanoma	0.000781	0.00356	CcSEcCtD
Pentoxifylline—Angioedema—Temozolomide—melanoma	0.000777	0.00354	CcSEcCtD
Pentoxifylline—Pancytopenia—Docetaxel—melanoma	0.00077	0.00351	CcSEcCtD
Pentoxifylline—Hypotension—Bleomycin—melanoma	0.000768	0.0035	CcSEcCtD
Pentoxifylline—Oedema—Dactinomycin—melanoma	0.000767	0.0035	CcSEcCtD
Pentoxifylline—Malaise—Temozolomide—melanoma	0.000767	0.00349	CcSEcCtD
Pentoxifylline—Convulsion—Carmustine—melanoma	0.000762	0.00347	CcSEcCtD
Pentoxifylline—Infection—Dactinomycin—melanoma	0.000762	0.00347	CcSEcCtD
Pentoxifylline—Leukopenia—Temozolomide—melanoma	0.000761	0.00347	CcSEcCtD
Pentoxifylline—Hypertension—Carmustine—melanoma	0.000759	0.00346	CcSEcCtD
Pentoxifylline—Palpitations—Temozolomide—melanoma	0.000751	0.00342	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Dactinomycin—melanoma	0.000751	0.00342	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Bleomycin—melanoma	0.000749	0.00342	CcSEcCtD
Pentoxifylline—Myalgia—Carmustine—melanoma	0.000749	0.00341	CcSEcCtD
Pentoxifylline—Chest pain—Carmustine—melanoma	0.000749	0.00341	CcSEcCtD
Pentoxifylline—Anxiety—Carmustine—melanoma	0.000746	0.0034	CcSEcCtD
Pentoxifylline—Convulsion—Temozolomide—melanoma	0.000736	0.00336	CcSEcCtD
Pentoxifylline—Hypertension—Temozolomide—melanoma	0.000734	0.00335	CcSEcCtD
Pentoxifylline—Dyspnoea—Bleomycin—melanoma	0.000733	0.00334	CcSEcCtD
Pentoxifylline—Anorexia—Dactinomycin—melanoma	0.000731	0.00333	CcSEcCtD
Pentoxifylline—Confusional state—Carmustine—melanoma	0.000724	0.0033	CcSEcCtD
Pentoxifylline—Myalgia—Temozolomide—melanoma	0.000724	0.0033	CcSEcCtD
Pentoxifylline—Infestation—Docetaxel—melanoma	0.000723	0.0033	CcSEcCtD
Pentoxifylline—Infestation NOS—Docetaxel—melanoma	0.000723	0.0033	CcSEcCtD
Pentoxifylline—Anxiety—Temozolomide—melanoma	0.000721	0.00329	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000719	0.00328	CcSEcCtD
Pentoxifylline—Oedema—Carmustine—melanoma	0.000718	0.00327	CcSEcCtD
Pentoxifylline—Discomfort—Temozolomide—melanoma	0.000715	0.00326	CcSEcCtD
Pentoxifylline—Decreased appetite—Bleomycin—melanoma	0.000715	0.00326	CcSEcCtD
Pentoxifylline—Infection—Carmustine—melanoma	0.000713	0.00325	CcSEcCtD
Pentoxifylline—Dry mouth—Temozolomide—melanoma	0.000708	0.00323	CcSEcCtD
Pentoxifylline—Jaundice—Docetaxel—melanoma	0.000705	0.00321	CcSEcCtD
Pentoxifylline—Conjunctivitis—Docetaxel—melanoma	0.000703	0.00321	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Carmustine—melanoma	0.000703	0.0032	CcSEcCtD
Pentoxifylline—Tachycardia—Carmustine—melanoma	0.000701	0.00319	CcSEcCtD
Pentoxifylline—Confusional state—Temozolomide—melanoma	0.000699	0.00319	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000699	0.00319	CcSEcCtD
Pentoxifylline—Oedema—Temozolomide—melanoma	0.000694	0.00316	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Temozolomide—melanoma	0.000694	0.00316	CcSEcCtD
Pentoxifylline—Infection—Temozolomide—melanoma	0.000689	0.00314	CcSEcCtD
Pentoxifylline—Anorexia—Carmustine—melanoma	0.000684	0.00312	CcSEcCtD
Pentoxifylline—Hepatobiliary disease—Docetaxel—melanoma	0.000684	0.00312	CcSEcCtD
Pentoxifylline—Epistaxis—Docetaxel—melanoma	0.000682	0.00311	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Temozolomide—melanoma	0.000679	0.0031	CcSEcCtD
Pentoxifylline—Feeling abnormal—Bleomycin—melanoma	0.000678	0.00309	CcSEcCtD
Pentoxifylline—Skin disorder—Temozolomide—melanoma	0.000674	0.00307	CcSEcCtD
Pentoxifylline—Hypotension—Carmustine—melanoma	0.000671	0.00306	CcSEcCtD
Pentoxifylline—Hyperhidrosis—Temozolomide—melanoma	0.000671	0.00306	CcSEcCtD
Pentoxifylline—Decreased appetite—Dactinomycin—melanoma	0.000667	0.00304	CcSEcCtD
Pentoxifylline—Anorexia—Temozolomide—melanoma	0.000661	0.00301	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Carmustine—melanoma	0.000654	0.00298	CcSEcCtD
Pentoxifylline—Urticaria—Bleomycin—melanoma	0.000653	0.00298	CcSEcCtD
Pentoxifylline—Haemoglobin—Docetaxel—melanoma	0.000653	0.00298	CcSEcCtD
Pentoxifylline—Body temperature increased—Bleomycin—melanoma	0.00065	0.00296	CcSEcCtD
Pentoxifylline—Haemorrhage—Docetaxel—melanoma	0.000649	0.00296	CcSEcCtD
Pentoxifylline—Hepatitis—Docetaxel—melanoma	0.000649	0.00296	CcSEcCtD
Pentoxifylline—Insomnia—Carmustine—melanoma	0.000649	0.00296	CcSEcCtD
Pentoxifylline—Dyspnoea—Carmustine—melanoma	0.00064	0.00292	CcSEcCtD
Pentoxifylline—Somnolence—Carmustine—melanoma	0.000638	0.00291	CcSEcCtD
Pentoxifylline—Feeling abnormal—Dactinomycin—melanoma	0.000632	0.00288	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Temozolomide—melanoma	0.000632	0.00288	CcSEcCtD
Pentoxifylline—Insomnia—Temozolomide—melanoma	0.000627	0.00286	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Dactinomycin—melanoma	0.000627	0.00286	CcSEcCtD
Pentoxifylline—Decreased appetite—Carmustine—melanoma	0.000624	0.00284	CcSEcCtD
Pentoxifylline—Dyspnoea—Temozolomide—melanoma	0.000618	0.00282	CcSEcCtD
Pentoxifylline—Somnolence—Temozolomide—melanoma	0.000617	0.00281	CcSEcCtD
Pentoxifylline—Constipation—Carmustine—melanoma	0.000614	0.0028	CcSEcCtD
Pentoxifylline—Dyspepsia—Temozolomide—melanoma	0.000611	0.00278	CcSEcCtD
Pentoxifylline—Abdominal pain—Dactinomycin—melanoma	0.000606	0.00276	CcSEcCtD
Pentoxifylline—Body temperature increased—Dactinomycin—melanoma	0.000606	0.00276	CcSEcCtD
Pentoxifylline—Hypersensitivity—Bleomycin—melanoma	0.000606	0.00276	CcSEcCtD
Pentoxifylline—Decreased appetite—Temozolomide—melanoma	0.000603	0.00275	CcSEcCtD
Pentoxifylline—Flushing—Docetaxel—melanoma	0.000603	0.00275	CcSEcCtD
Pentoxifylline—Constipation—Temozolomide—melanoma	0.000593	0.0027	CcSEcCtD
Pentoxifylline—Feeling abnormal—Carmustine—melanoma	0.000592	0.0027	CcSEcCtD
Pentoxifylline—Asthenia—Bleomycin—melanoma	0.00059	0.00269	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Carmustine—melanoma	0.000587	0.00268	CcSEcCtD
Pentoxifylline—Immune system disorder—Docetaxel—melanoma	0.000587	0.00267	CcSEcCtD
Pentoxifylline—Pruritus—Bleomycin—melanoma	0.000582	0.00265	CcSEcCtD
Pentoxifylline—Arrhythmia—Docetaxel—melanoma	0.00058	0.00264	CcSEcCtD
Pentoxifylline—Feeling abnormal—Temozolomide—melanoma	0.000572	0.00261	CcSEcCtD
Pentoxifylline—Abdominal pain—Carmustine—melanoma	0.000567	0.00259	CcSEcCtD
Pentoxifylline—Body temperature increased—Carmustine—melanoma	0.000567	0.00259	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Temozolomide—melanoma	0.000567	0.00259	CcSEcCtD
Pentoxifylline—Erythema—Docetaxel—melanoma	0.000565	0.00258	CcSEcCtD
Pentoxifylline—Hypersensitivity—Dactinomycin—melanoma	0.000565	0.00258	CcSEcCtD
Pentoxifylline—Dysgeusia—Docetaxel—melanoma	0.000554	0.00252	CcSEcCtD
Pentoxifylline—Urticaria—Temozolomide—melanoma	0.000551	0.00251	CcSEcCtD
Pentoxifylline—Asthenia—Dactinomycin—melanoma	0.00055	0.00251	CcSEcCtD
Pentoxifylline—Abdominal pain—Temozolomide—melanoma	0.000548	0.0025	CcSEcCtD
Pentoxifylline—Body temperature increased—Temozolomide—melanoma	0.000548	0.0025	CcSEcCtD
Pentoxifylline—Back pain—Docetaxel—melanoma	0.000547	0.00249	CcSEcCtD
Pentoxifylline—Muscle spasms—Docetaxel—melanoma	0.000543	0.00248	CcSEcCtD
Pentoxifylline—Hypersensitivity—Carmustine—melanoma	0.000529	0.00241	CcSEcCtD
Pentoxifylline—Diarrhoea—Dactinomycin—melanoma	0.000525	0.00239	CcSEcCtD
Pentoxifylline—Vomiting—Bleomycin—melanoma	0.000523	0.00238	CcSEcCtD
Pentoxifylline—Anaemia—Docetaxel—melanoma	0.000522	0.00238	CcSEcCtD
Pentoxifylline—Rash—Bleomycin—melanoma	0.000519	0.00236	CcSEcCtD
Pentoxifylline—Dermatitis—Bleomycin—melanoma	0.000518	0.00236	CcSEcCtD
Pentoxifylline—Asthenia—Carmustine—melanoma	0.000515	0.00235	CcSEcCtD
Pentoxifylline—Hypersensitivity—Temozolomide—melanoma	0.000511	0.00233	CcSEcCtD
Pentoxifylline—Leukopenia—Docetaxel—melanoma	0.000506	0.00231	CcSEcCtD
Pentoxifylline—Palpitations—Docetaxel—melanoma	0.0005	0.00228	CcSEcCtD
Pentoxifylline—Asthenia—Temozolomide—melanoma	0.000498	0.00227	CcSEcCtD
Pentoxifylline—Diarrhoea—Carmustine—melanoma	0.000491	0.00224	CcSEcCtD
Pentoxifylline—Pruritus—Temozolomide—melanoma	0.000491	0.00224	CcSEcCtD
Pentoxifylline—Convulsion—Docetaxel—melanoma	0.00049	0.00223	CcSEcCtD
Pentoxifylline—Nausea—Bleomycin—melanoma	0.000488	0.00223	CcSEcCtD
Pentoxifylline—Hypertension—Docetaxel—melanoma	0.000488	0.00222	CcSEcCtD
Pentoxifylline—Vomiting—Dactinomycin—melanoma	0.000488	0.00222	CcSEcCtD
Pentoxifylline—Rash—Dactinomycin—melanoma	0.000484	0.0022	CcSEcCtD
Pentoxifylline—Chest pain—Docetaxel—melanoma	0.000481	0.00219	CcSEcCtD
Pentoxifylline—Myalgia—Docetaxel—melanoma	0.000481	0.00219	CcSEcCtD
Pentoxifylline—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000478	0.00218	CcSEcCtD
Pentoxifylline—Dizziness—Carmustine—melanoma	0.000475	0.00216	CcSEcCtD
Pentoxifylline—Diarrhoea—Temozolomide—melanoma	0.000475	0.00216	CcSEcCtD
Pentoxifylline—Dry mouth—Docetaxel—melanoma	0.000471	0.00215	CcSEcCtD
Pentoxifylline—Confusional state—Docetaxel—melanoma	0.000465	0.00212	CcSEcCtD
Pentoxifylline—Anaphylactic shock—Docetaxel—melanoma	0.000461	0.0021	CcSEcCtD
Pentoxifylline—Oedema—Docetaxel—melanoma	0.000461	0.0021	CcSEcCtD
Pentoxifylline—Dizziness—Temozolomide—melanoma	0.000459	0.00209	CcSEcCtD
Pentoxifylline—Infection—Docetaxel—melanoma	0.000458	0.00209	CcSEcCtD
Pentoxifylline—Vomiting—Carmustine—melanoma	0.000456	0.00208	CcSEcCtD
Pentoxifylline—Nausea—Dactinomycin—melanoma	0.000456	0.00208	CcSEcCtD
Pentoxifylline—Shock—Docetaxel—melanoma	0.000454	0.00207	CcSEcCtD
Pentoxifylline—Rash—Carmustine—melanoma	0.000453	0.00206	CcSEcCtD
Pentoxifylline—Dermatitis—Carmustine—melanoma	0.000452	0.00206	CcSEcCtD
Pentoxifylline—Thrombocytopenia—Docetaxel—melanoma	0.000452	0.00206	CcSEcCtD
Pentoxifylline—Tachycardia—Docetaxel—melanoma	0.00045	0.00205	CcSEcCtD
Pentoxifylline—Headache—Carmustine—melanoma	0.00045	0.00205	CcSEcCtD
Pentoxifylline—Skin disorder—Docetaxel—melanoma	0.000448	0.00204	CcSEcCtD
Pentoxifylline—Vomiting—Temozolomide—melanoma	0.000441	0.00201	CcSEcCtD
Pentoxifylline—Anorexia—Docetaxel—melanoma	0.00044	0.002	CcSEcCtD
Pentoxifylline—Rash—Temozolomide—melanoma	0.000437	0.00199	CcSEcCtD
Pentoxifylline—Dermatitis—Temozolomide—melanoma	0.000437	0.00199	CcSEcCtD
Pentoxifylline—Headache—Temozolomide—melanoma	0.000435	0.00198	CcSEcCtD
Pentoxifylline—Hypotension—Docetaxel—melanoma	0.000431	0.00197	CcSEcCtD
Pentoxifylline—Nausea—Carmustine—melanoma	0.000426	0.00194	CcSEcCtD
Pentoxifylline—Musculoskeletal discomfort—Docetaxel—melanoma	0.00042	0.00192	CcSEcCtD
Pentoxifylline—Insomnia—Docetaxel—melanoma	0.000417	0.0019	CcSEcCtD
Pentoxifylline—Nausea—Temozolomide—melanoma	0.000412	0.00188	CcSEcCtD
Pentoxifylline—Dyspnoea—Docetaxel—melanoma	0.000411	0.00187	CcSEcCtD
Pentoxifylline—Somnolence—Docetaxel—melanoma	0.00041	0.00187	CcSEcCtD
Pentoxifylline—Dyspepsia—Docetaxel—melanoma	0.000406	0.00185	CcSEcCtD
Pentoxifylline—Decreased appetite—Docetaxel—melanoma	0.000401	0.00183	CcSEcCtD
Pentoxifylline—Constipation—Docetaxel—melanoma	0.000395	0.0018	CcSEcCtD
Pentoxifylline—Feeling abnormal—Docetaxel—melanoma	0.00038	0.00173	CcSEcCtD
Pentoxifylline—Gastrointestinal pain—Docetaxel—melanoma	0.000377	0.00172	CcSEcCtD
Pentoxifylline—Body temperature increased—Docetaxel—melanoma	0.000365	0.00166	CcSEcCtD
Pentoxifylline—Abdominal pain—Docetaxel—melanoma	0.000365	0.00166	CcSEcCtD
Pentoxifylline—Caffeine—ABCB1—melanoma	0.000364	0.0211	CrCbGaD
Pentoxifylline—Hypersensitivity—Docetaxel—melanoma	0.00034	0.00155	CcSEcCtD
Pentoxifylline—Asthenia—Docetaxel—melanoma	0.000331	0.00151	CcSEcCtD
Pentoxifylline—Pruritus—Docetaxel—melanoma	0.000326	0.00149	CcSEcCtD
Pentoxifylline—Diarrhoea—Docetaxel—melanoma	0.000316	0.00144	CcSEcCtD
Pentoxifylline—Dizziness—Docetaxel—melanoma	0.000305	0.00139	CcSEcCtD
Pentoxifylline—Vomiting—Docetaxel—melanoma	0.000293	0.00134	CcSEcCtD
Pentoxifylline—Rash—Docetaxel—melanoma	0.000291	0.00133	CcSEcCtD
Pentoxifylline—Dermatitis—Docetaxel—melanoma	0.000291	0.00132	CcSEcCtD
Pentoxifylline—Headache—Docetaxel—melanoma	0.000289	0.00132	CcSEcCtD
Pentoxifylline—Nausea—Docetaxel—melanoma	0.000274	0.00125	CcSEcCtD
Pentoxifylline—ADORA2A—Signaling Pathways—PRKCA—melanoma	3.29e-05	0.000125	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ITGB3—melanoma	3.29e-05	0.000125	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IGF1—melanoma	3.27e-05	0.000124	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—EGF—melanoma	3.26e-05	0.000124	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—MAPK1—melanoma	3.25e-05	0.000123	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—EGFR—melanoma	3.25e-05	0.000123	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	3.24e-05	0.000123	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—SPP1—melanoma	3.23e-05	0.000122	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MAP2K2—melanoma	3.22e-05	0.000122	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—CXCL8—melanoma	3.22e-05	0.000122	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—MAPK3—melanoma	3.2e-05	0.000121	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—MAPK3—melanoma	3.16e-05	0.00012	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MAP2K1—melanoma	3.16e-05	0.00012	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—BRAF—melanoma	3.14e-05	0.000119	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CD—melanoma	3.14e-05	0.000119	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—PIK3CA—melanoma	3.11e-05	0.000118	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—PIK3CA—melanoma	3.11e-05	0.000118	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—BRAF—melanoma	3.1e-05	0.000118	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MDM2—melanoma	3.09e-05	0.000117	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL2—melanoma	3.07e-05	0.000117	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—KRAS—melanoma	3.07e-05	0.000116	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TERT—melanoma	3.06e-05	0.000116	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IGF1—melanoma	3.06e-05	0.000116	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—RAC1—melanoma	3.05e-05	0.000116	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—ERBB2—melanoma	3.05e-05	0.000116	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—MAPK1—melanoma	3.04e-05	0.000115	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—EGFR—melanoma	3.04e-05	0.000115	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IGF1—melanoma	3.02e-05	0.000115	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PIK3CB—melanoma	3.01e-05	0.000114	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—MAPK1—melanoma	3.01e-05	0.000114	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—EGFR—melanoma	3.01e-05	0.000114	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—FGF2—melanoma	3e-05	0.000114	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MAP2K1—melanoma	2.96e-05	0.000112	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PHGDH—melanoma	2.95e-05	0.000112	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—LUM—melanoma	2.95e-05	0.000112	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CD—melanoma	2.94e-05	0.000111	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—HIF1A—melanoma	2.93e-05	0.000111	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MAP2K1—melanoma	2.92e-05	0.000111	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—PIK3CA—melanoma	2.91e-05	0.00011	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CD—melanoma	2.9e-05	0.00011	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—HPSE—melanoma	2.9e-05	0.00011	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CXCL8—melanoma	2.89e-05	0.00011	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—KRAS—melanoma	2.88e-05	0.000109	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—PIK3CA—melanoma	2.87e-05	0.000109	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—HRAS—melanoma	2.87e-05	0.000109	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CUBN—melanoma	2.84e-05	0.000108	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—KRAS—melanoma	2.84e-05	0.000108	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CDKN1B—melanoma	2.83e-05	0.000107	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—PIK3CA—melanoma	2.82e-05	0.000107	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—FGF2—melanoma	2.81e-05	0.000107	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MDM2—melanoma	2.81e-05	0.000107	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KDR—melanoma	2.8e-05	0.000106	CbGpPWpGaD
Pentoxifylline—ADORA2B—GPCR downstream signaling—AKT1—melanoma	2.8e-05	0.000106	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—FGF2—melanoma	2.78e-05	0.000105	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—ERBB2—melanoma	2.77e-05	0.000105	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CASP3—melanoma	2.77e-05	0.000105	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL2—melanoma	2.77e-05	0.000105	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—IL6—melanoma	2.75e-05	0.000104	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—BSG—melanoma	2.75e-05	0.000104	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CSPG4—melanoma	2.75e-05	0.000104	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SDHD—melanoma	2.75e-05	0.000104	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CB—melanoma	2.73e-05	0.000104	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CCND1—melanoma	2.7e-05	0.000102	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—FN1—melanoma	2.7e-05	0.000102	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CTNNB1—melanoma	2.67e-05	0.000101	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GPAM—melanoma	2.66e-05	0.000101	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—PIK3CA—melanoma	2.64e-05	0.0001	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NOTCH1—melanoma	2.64e-05	0.0001	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MDM2—melanoma	2.63e-05	9.98e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CXCL8—melanoma	2.63e-05	9.96e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MMP9—melanoma	2.62e-05	9.92e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—PIK3CA—melanoma	2.61e-05	9.9e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—HRAS—melanoma	2.61e-05	9.9e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—CDKN1A—melanoma	2.61e-05	9.89e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PTEN—melanoma	2.6e-05	9.87e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MDM2—melanoma	2.6e-05	9.86e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—ERBB2—melanoma	2.59e-05	9.84e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NFKB1—melanoma	2.59e-05	9.82e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CD80—melanoma	2.58e-05	9.8e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CG—melanoma	2.58e-05	9.78e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KIT—melanoma	2.58e-05	9.78e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—APC—melanoma	2.58e-05	9.78e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—NRAS—melanoma	2.58e-05	9.78e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CDKN1B—melanoma	2.57e-05	9.73e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—ERBB2—melanoma	2.56e-05	9.72e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CB—melanoma	2.56e-05	9.71e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EGF—melanoma	2.55e-05	9.67e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling by GPCR—AKT1—melanoma	2.54e-05	9.63e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—GPCR downstream signaling—AKT1—melanoma	2.54e-05	9.63e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CB—melanoma	2.53e-05	9.59e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CASP3—melanoma	2.51e-05	9.54e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL2—melanoma	2.51e-05	9.52e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—IL6—melanoma	2.5e-05	9.47e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—MAPK3—melanoma	2.47e-05	9.37e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CXCL8—melanoma	2.46e-05	9.33e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CCND1—melanoma	2.45e-05	9.28e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—HRAS—melanoma	2.44e-05	9.27e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CXCL8—melanoma	2.43e-05	9.22e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—BRAF—melanoma	2.42e-05	9.2e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CTNNB1—melanoma	2.42e-05	9.19e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—HRAS—melanoma	2.42e-05	9.16e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CDKN1B—melanoma	2.4e-05	9.11e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—GPCR downstream signaling—AKT1—melanoma	2.38e-05	9.01e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MMP9—melanoma	2.38e-05	9.01e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CDKN1B—melanoma	2.37e-05	9e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—CDKN1A—melanoma	2.37e-05	8.98e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PTEN—melanoma	2.36e-05	8.96e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IGF1—melanoma	2.36e-05	8.96e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CASP3—melanoma	2.35e-05	8.93e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NFKB1—melanoma	2.35e-05	8.92e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL2—melanoma	2.35e-05	8.92e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—MAPK1—melanoma	2.35e-05	8.91e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—EGFR—melanoma	2.35e-05	8.91e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—VEGFA—melanoma	2.35e-05	8.91e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—GPCR downstream signaling—AKT1—melanoma	2.35e-05	8.91e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—IL6—melanoma	2.34e-05	8.87e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—STAT3—melanoma	2.33e-05	8.82e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CASP3—melanoma	2.33e-05	8.82e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL2—melanoma	2.32e-05	8.81e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—NRAS—melanoma	2.32e-05	8.8e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—IL6—melanoma	2.31e-05	8.77e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling by GPCR—AKT1—melanoma	2.3e-05	8.74e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CCND1—melanoma	2.29e-05	8.69e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MAP2K1—melanoma	2.28e-05	8.66e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CTNNB1—melanoma	2.27e-05	8.61e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CD—melanoma	2.27e-05	8.6e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CCND1—melanoma	2.26e-05	8.59e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PLA2G6—melanoma	2.26e-05	8.58e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—PIK3CA—melanoma	2.25e-05	8.52e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CTNNB1—melanoma	2.24e-05	8.51e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MMP9—melanoma	2.23e-05	8.44e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MAPK3—melanoma	2.22e-05	8.43e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—KRAS—melanoma	2.22e-05	8.42e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—CDKN1A—melanoma	2.22e-05	8.41e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PTEN—melanoma	2.21e-05	8.39e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NFKB1—melanoma	2.2e-05	8.35e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MMP9—melanoma	2.2e-05	8.34e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—CDKN1A—melanoma	2.19e-05	8.31e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PTEN—melanoma	2.19e-05	8.29e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NFKB1—melanoma	2.18e-05	8.25e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—FGF2—melanoma	2.17e-05	8.23e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MYC—melanoma	2.16e-05	8.2e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling by GPCR—AKT1—melanoma	2.16e-05	8.18e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—VEGFA—melanoma	2.13e-05	8.09e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling by GPCR—AKT1—melanoma	2.13e-05	8.09e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—MAPK1—melanoma	2.12e-05	8.02e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—EGFR—melanoma	2.11e-05	8.02e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—STAT3—melanoma	2.11e-05	8.01e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—NRAS—melanoma	2.11e-05	7.99e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—PIK3CA—melanoma	2.04e-05	7.74e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MDM2—melanoma	2.03e-05	7.7e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—VCAN—melanoma	2.03e-05	7.7e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MAPK3—melanoma	2.02e-05	7.66e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—ERBB2—melanoma	2e-05	7.6e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—VEGFA—melanoma	2e-05	7.58e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—KRAS—melanoma	2e-05	7.58e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—STAT3—melanoma	1.98e-05	7.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CB—melanoma	1.98e-05	7.5e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—VEGFA—melanoma	1.97e-05	7.49e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—NRAS—melanoma	1.97e-05	7.48e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MYC—melanoma	1.96e-05	7.45e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—STAT3—melanoma	1.96e-05	7.41e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—NRAS—melanoma	1.95e-05	7.4e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.92e-05	7.29e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—MAPK1—melanoma	1.92e-05	7.28e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—EGFR—melanoma	1.92e-05	7.28e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CXCL8—melanoma	1.9e-05	7.2e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MAPK3—melanoma	1.89e-05	7.17e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—HRAS—melanoma	1.89e-05	7.16e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MAPK3—melanoma	1.87e-05	7.08e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.86e-05	7.04e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CDKN1B—melanoma	1.86e-05	7.03e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MYC—melanoma	1.84e-05	6.97e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—PIK3CA—melanoma	1.84e-05	6.96e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—GPCR downstream signaling—AKT1—melanoma	1.84e-05	6.96e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CASP3—melanoma	1.82e-05	6.89e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MYC—melanoma	1.82e-05	6.89e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL2—melanoma	1.82e-05	6.88e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—KRAS—melanoma	1.81e-05	6.88e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—IL6—melanoma	1.81e-05	6.85e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—MAPK1—melanoma	1.8e-05	6.82e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—EGFR—melanoma	1.8e-05	6.82e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—MAPK1—melanoma	1.78e-05	6.74e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—EGFR—melanoma	1.78e-05	6.74e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—TP53—melanoma	1.78e-05	6.73e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CCND1—melanoma	1.77e-05	6.71e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CTNNB1—melanoma	1.75e-05	6.65e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MMP9—melanoma	1.72e-05	6.52e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP17A1—melanoma	1.71e-05	6.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—CDKN1A—melanoma	1.71e-05	6.49e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PTEN—melanoma	1.71e-05	6.48e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NFKB1—melanoma	1.7e-05	6.45e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—KRAS—melanoma	1.7e-05	6.44e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—HRAS—melanoma	1.7e-05	6.44e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.69e-05	6.41e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—KRAS—melanoma	1.68e-05	6.37e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—ALB—melanoma	1.67e-05	6.33e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—PIK3CA—melanoma	1.67e-05	6.32e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling by GPCR—AKT1—melanoma	1.67e-05	6.32e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—IL6—melanoma	1.63e-05	6.16e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GNA11—melanoma	1.62e-05	6.14e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—TP53—melanoma	1.61e-05	6.11e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—FASN—melanoma	1.58e-05	6.01e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—PIK3CA—melanoma	1.56e-05	5.92e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—SLC5A5—melanoma	1.56e-05	5.91e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—VEGFA—melanoma	1.54e-05	5.85e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—PIK3CA—melanoma	1.54e-05	5.85e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—HRAS—melanoma	1.54e-05	5.85e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—STAT3—melanoma	1.53e-05	5.79e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—NRAS—melanoma	1.52e-05	5.78e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—TP53—melanoma	1.51e-05	5.73e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—GNAQ—melanoma	1.5e-05	5.71e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CD44—melanoma	1.5e-05	5.71e-05	CbGpPWpGaD
Pentoxifylline—ADORA2B—Signaling Pathways—AKT1—melanoma	1.5e-05	5.69e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—TP53—melanoma	1.49e-05	5.66e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—IL6—melanoma	1.48e-05	5.6e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.47e-05	5.59e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.46e-05	5.54e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MAPK3—melanoma	1.46e-05	5.53e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—HRAS—melanoma	1.44e-05	5.48e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—CYP1B1—melanoma	1.44e-05	5.47e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—HRAS—melanoma	1.43e-05	5.41e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MYC—melanoma	1.42e-05	5.38e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—MAPK1—melanoma	1.39e-05	5.27e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—EGFR—melanoma	1.39e-05	5.27e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—IL6—melanoma	1.38e-05	5.24e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—IL6—melanoma	1.37e-05	5.18e-05	CbGpPWpGaD
Pentoxifylline—PDE4A—Signaling Pathways—AKT1—melanoma	1.36e-05	5.16e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—KRAS—melanoma	1.31e-05	4.97e-05	CbGpPWpGaD
Pentoxifylline—ADORA1—Signaling Pathways—AKT1—melanoma	1.27e-05	4.83e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.27e-05	4.83e-05	CbGpPWpGaD
Pentoxifylline—PDE4B—Signaling Pathways—AKT1—melanoma	1.26e-05	4.78e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—PIK3CA—melanoma	1.21e-05	4.57e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ABCB1—melanoma	1.19e-05	4.5e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—TP53—melanoma	1.17e-05	4.42e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—HRAS—melanoma	1.11e-05	4.23e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PRKCA—melanoma	1.09e-05	4.15e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ERCC2—melanoma	1.08e-05	4.11e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—IL6—melanoma	1.07e-05	4.05e-05	CbGpPWpGaD
Pentoxifylline—ADORA2A—Signaling Pathways—AKT1—melanoma	9.84e-06	3.73e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	8.98e-06	3.41e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CG—melanoma	8.56e-06	3.25e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PPARG—melanoma	8.26e-06	3.13e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CD—melanoma	7.53e-06	2.85e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—ALB—melanoma	7.43e-06	2.82e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CB—melanoma	6.56e-06	2.49e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTGS2—melanoma	6.5e-06	2.47e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PTEN—melanoma	5.67e-06	2.15e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—PIK3CA—melanoma	4e-06	1.52e-05	CbGpPWpGaD
Pentoxifylline—CYP1A2—Metabolism—AKT1—melanoma	3.27e-06	1.24e-05	CbGpPWpGaD
